Approval · Notice of Compliance 30133 · 2023
RESTASIS MULTIDOSE: Notice of Compliance 30133
Issued February 16, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30133
- Date
- February 16, 2023
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of manufacturing site of the drug product, change in specification of the drug product tests, change in fill volume, and conversion of the Product Monograph (PM) to the Master Template
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RESTASIS MULTIDOSE | Not yet assigned | — |
Medicinal ingredients
- CYCLOSPORINE 0.05 PER